Omnicom, Achieve Life Sciences Partner for AI-Driven Launch of New Nicotine Dependence Treatment

Omnicom Group Inc. (NYSE:OMC) is one of the best high short interest stocks with huge upside potential. On June 26, Achieve Life Sciences Inc. (NASDAQ:ACHV) announced a strategic innovation partnership with Omnicom. Omnicom has been named Achieve’s agency of record to lead initiatives for the US commercial launch of cytisinicline, which is positioned to be the first potential new treatment for nicotine dependence in nearly two decades.

The expanded partnership builds on an existing relationship and aims for a technology-led, integrated, and data-driven launch strategy. The US launch platform for cytisinicline is being developed by Credera, which is Omnicom’s technology powerhouse and uses AI-enabled marketing technology proven in healthcare and other industries for precise targeting, optimized channel performance, and accelerated engagement with healthcare professionals and patients.

Omnicom, Achieve Life Sciences Partner for AI-Driven Launch of New Nicotine Dependence Treatment

A social media specialist crafting new ideas for healthcare marketing campaigns on a laptop.

Omnicom has assembled a unified agency team that draws on specialized talent from Goodby, Silverstein & Partners for consumer brand development, DDB Health for medical education, and Ketchum Health for strategic public relations and communications. The cross-functional approach applies proven insights from different industries to set a new standard for biopharma commercialization.

Omnicom Group Inc. (NYSE:OMC) offers advertising, marketing, and corporate communications services. Achieve Life Sciences Inc. (NASDAQ:ACHV) is a late-stage pharmaceutical company that develops and commercializes cytisinicline for nicotine independence in Canada, the US, and the UK.

While we acknowledge the potential of OMC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.